Showing 1471-1480 of 23118 results for "".
Treatment Options for Painful Intercourse in Menopausal Women
https://reachmd.com/programs/clinicians-roundtable/treatment-options-for-painful-intercourse-menopausal-women/7738/For women entering menopause, increased pain during intercourse is a common but little discussed problem which dramatically affects quality of life. While there are several treatment options available, many clinicians aren't up to date. Joining host Dr. Tom Wright to discuss current therapies for paCan We Do Better in IgAN?
https://reachmd.com/programs/cme/can-we-do-better-in-igan/14977/What are the limitations of existing therapies in IgAN, and how can emerging therapies complement treatment strategies? Find out from our experts!Supplementary Motor Area Glioma Presenting with Musicogenic Epilepsy: “Singing Seizures”
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/supplementary-motor-area-glioma-presenting-with-musicogenic-epilepsy-singing-seizures/32090/Recognition of musicogenic epilepsy should prompt a standard seizure workup to include neuroimaging.Conquer the Clutter: Strategies to Identify, Manage, & Overcome Hoarding
https://reachmd.com/programs/book-club/conquer-the-clutter-strategies-to-identify-manage-overcome-hoarding/11245/As many as 21 million Americans may be living with hoarding disorder. How can we help them reclaim their lives from the clutter that’s taken over?Molecular Precision: How Myosin Inhibitors Redefine Control
https://reachmd.com/programs/cme/molecular-precision-how-myosin-inhibitors-redefine-control/54839/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
https://reachmd.com/programs/cme/from-beta-blockers-to-myosin-inhibitors-initial-decision-making-in-obstructive-hcm/54843/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Cracking the Code of Obstruction: Unmet Needs in oHCM
https://reachmd.com/programs/cme/cracking-the-code-of-obstruction-unmet-needs-in-ohcm/54837/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
https://reachmd.com/programs/cme/redefining-ohcm-care-efficacy-and-safety-of-myosin-inhibitors/54840/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Hidden in Plain Sight: A Modern Guide to Detecting and Managing Early Neurotrophic Keratitis
https://reachmd.com/programs/cme/hidden-in-plain-sight-a-modern-guide-to-detecting-and-managing-early-neurotrophic-keratitis/54091/Can you detect NK early and accurately? Join our experts to learn about the most effective diagnostic strategies and best practices in the management of NK.Expanding Treatment Options in PNH: Expert Approaches to Personalized Care
https://reachmd.com/programs/medical-industry-feature/pnh-expert-approaches-personalized-care/35651/Managing patients with paroxysmal nocturnal hemoglobinuria (PNH) is never a “one-size-fits-all” approach. With the emergence of a therapy like FABHALTA® (iptacopan), which delivers comprehensive control of intravascular and extravascular hemolysis, we have an option to offer to eligible adult patien